Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Leerink Partners Downgrades Affimed Therapeutics (AFMD) to Market Perform
August 12, 2016 7:41 AM EDTLeerink Partners downgraded Affimed Therapeutics (NASDAQ: AFMD) from Outperform to Market Perform with a price target of $3.00 (from $8.00).
Analyst Michael Schmidt commented, "We are downgrading shares of AFMD to Market Perform, given that the company's two clinical stage product candidates are... More
Affimed (AFMD) Misses Q2 EPS by 1c; CMO Marschner to Resign
August 10, 2016 7:36 AM EDTAffimed (NASDAQ: AFMD) reported Q2 EPS of (EUR0.24), EUR0.01 worse than the analyst estimate of (EUR0.23).
Affimed announced that the Companys Chief Medical Officer, Dr. Jens-Peter Marschner, has decided to step down as CMO. Since joining the Company in 2013, Dr. Marschner has... More
